VivoSim Labs, INC. (VIVS): Results of Operations and Financial Condition
VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t
How this was made
The 30-second read
Why it matters
The Nasdaq Staff determination can remove a near-term overhang tied to minimum stockholders’ equity, while the reported cash balance and forward revenue growth expectations influence valuation and financing-risk perceptions.
Market read
This is a single-name microcap catalyst: Nasdaq compliance confirmation plus preliminary liquidity data can shift risk pricing immediately, but the lack of audited results limits conviction.
What to watch
Traders may focus on whether the company’s equity level is stable going forward and whether the 8-K’s preliminary estimates later change in the next quarterly filing.
VivoSim Labs reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, confirmed compliance with Nasdaq Listing Rule 5550(b)(1), and anticipates 500%+ revenue growth in fiscal year 2027.
The filing provides a favorable fiscal year 2027 revenue-growth outlook and confirms Nasdaq minimum-stockholders'-equity compliance, but it does not disclose reported-period revenue, profitability, margins, cash flow, or operating metrics. The cash figure is preliminary and subject to financial closing procedures and final adjustments.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Preliminary cash on handother | approximately $10.1 million | – | – |
fiscal year 2027 outlook
- Revenue500%+ revenue growth
What drove it
- The Company anticipates 500%+ revenue growth in its fiscal year 2027.
- The Nasdaq Listing Qualifications Staff determined that the Company currently complies with Nasdaq Listing Rule 5550(b)(1), which requires registrants to maintain a minimum stockholders’ equity balance of $2.5 million.
Concerns
- The preliminary financial information reflects management’s current estimates and could be impacted by financial closing procedures, final adjustments, and other developments.
- The filing does not provide an actual revenue figure, profitability measures, margins, operating cash flow, free cash flow, or debt.
- The fiscal year 2027 revenue outlook is expressed only as 500%+ revenue growth, without a revenue base, revenue range, or other financial guidance.
What to watch
- Finalization of the preliminary cash-on-hand figure following financial closing procedures and final adjustments.
- Reported fiscal year 2027 revenue and the base against which the anticipated 500%+ revenue growth will be measured.
- Continued compliance with Nasdaq Listing Rule 5550(b)(1).
Balance sheet and cash flow
- Preliminary cash on hand as of August 3, 2026 was approximately $10.1 million.
Analysis
This Item 2.02 filing is a preliminary financial and corporate-status update rather than a complete earnings release. VivoSim Labs disclosed preliminary cash on hand of approximately $10.1 million as of August 3, 2026, but did not provide a fiscal reporting period, income statement, balance sheet, or cash flow statement.
The principal forward-looking disclosure is that the Company anticipates 500%+ revenue growth in its fiscal year 2027. The filing does not state the revenue amount from which this growth will be measured, nor does it provide revenue guidance in dollars, segment detail, gross-margin guidance, operating-expense guidance, tax-rate guidance, or profitability targets.
The company also disclosed that Nasdaq Listing Qualifications Staff determined that it currently complies with Nasdaq Listing Rule 5550(b)(1). The filing describes that rule as requiring registrants to maintain a minimum stockholders’ equity balance of $2.5 million. This is a listing-compliance determination, not a reported stockholders’ equity balance for VivoSim Labs.
The preliminary nature of the cash disclosure is important. Management stated that the information is based on currently available information and could be affected by financial closing procedures, final adjustments, and other developments. Investors will need the underlying periodic financial statements to assess revenue conversion, operating losses or income, cash burn, debt, and the durability of the fiscal year 2027 growth outlook.
No capital-return activity, debt balance, operating cash flow, free cash flow, segment performance, GAAP results, non-GAAP results, or executive commentary was included in the provided filing text. Accordingly, the disclosed outlook and preliminary liquidity figure are the only financial datapoints available for this read.
Not in the filing
stated, not guessed- Fiscal reporting period and period-end date.
- Actual total revenue and prior-year and prior-quarter revenue comparisons.
- Revenue growth for any reported period.
- Segment revenue, segment growth rates, and segment drivers.
- GAAP gross profit, gross margin, operating expenses, operating income or loss, net income or loss, and earnings per share.
- Non-GAAP gross margin, operating income or loss, net income or loss, and earnings per share.
- Operating cash flow and free cash flow.
- Cash-flow comparisons to prior periods.
- Debt, reported stockholders’ equity, and other balance-sheet balances.
- Share repurchases, dividends, and other capital-return activity.
- Fiscal year 2027 revenue amount or range, revenue comparison base, gross-margin guidance, operating-expense guidance, tax-rate guidance, and other financial guidance.
- Prior-period guidance for comparison.
- Named executive quotes or CFO commentary.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The company filed an SEC 8-K (Item 2.02) attaching a press release about Nasdaq listing compliance and preliminary cash on hand.
Ticker impact
VivoSim Labs disclosed Nasdaq Staff determined it currently complies with Listing Rule 5550(b)(1) and reported preliminary cash of about $10.1M.
Likely modestly positive bias for VIVS as listing-risk overhang eases, but follow-through depends on whether the company can sustain equity and cash burn.
The filing is a fresh, company-specific regulatory compliance update plus preliminary liquidity data; however, it does not provide audited financial results or concrete revenue milestones beyond a forward-looking growth claim.
Market effects
Limited direct sector read-through; it is primarily a single-company listing-risk and liquidity update.
No clear regional spillover beyond US microcap sentiment.
Minimal global relevance; US Nasdaq listing compliance is company-specific.
Counterpoint
Nasdaq compliance does not eliminate future equity shortfalls; the preliminary cash number and aggressive 2027 growth claim may increase skepticism about burn and financing needs.
Key entities
- companyVivoSim Labs, Inc.
Nasdaq-listed registrant filing the 8-K with compliance and preliminary financial condition updates.
- regulatory_ruleNasdaq Listing Rule 5550(b)(1)
Minimum stockholders’ equity requirement of $2.5 million referenced in the compliance determination.
- regulatorListing Qualifications Staff of The Nasdaq Stock Market LLC
Provided the determination that the company currently complies with the rule.
